Drug

Denosumab (Xgeva)

A monthly injection under the skin to protect the bones in bone metastases and myeloma

Updated: 27 October 20262 min read3 references
Generic name
Denosumab
Brand names
Xgeva
Drug class
Anti-RANKL monoclonal antibody
Route
Subcutaneous injection
Show content for:

Key points

  • Denosumab is injected under the skin once a month so that bone the cancer has reached does not break [1].
  • In breast cancer that has spread to the bones, it delayed bone complications longer than zoledronic acid [2].
  • Calcium and vitamin D are needed with it; see a dentist before starting [1, 3].

What is this drug and how does it work?

For patients

Denosumab blocks the cells that break down bone. When cancer has spread to the bone, this lowers the risk of fractures, pressure on the spinal cord and the need for radiotherapy to the bone [1].

For physiciansSpecialist notes
For physicians

A human anti-RANKL antibody; inhibits osteoclast formation, function and survival [1].

Which cancers is it used for?

For patients
What is this drug for?
  • Preventing bone complications in bone metastases from solid tumours and in myeloma [1]
  • Giant cell tumour of bone and high blood calcium that does not respond to bisphosphonates [1]
For physiciansApproved uses and evidence
For physicians
Approved uses and evidence
DiseaseUseKey evidence
Bone metastases from solid tumours and myelomaPrevention of skeletal-related events [1]In breast cancer, delayed time to first skeletal-related event by 18% compared with zoledronic acid [2]
Hypercalcaemia of malignancy refractory to bisphosphonates[1]—
Giant cell tumour of bone[1]—

How it is taken and dosing

Show detailsHide

One injection under the skin of the upper arm, thigh or abdomen every 4 weeks at the clinic. Take calcium and vitamin D every day as your doctor directs, unless your blood calcium is high [1].

For physiciansStandard dosing (FDA label), 1 regimen
For physicians

Standard dosing (FDA label)

Denosumab

Bone metastases and myelomaCycle length: Every 4 weeks

Bone metastases and myeloma

DrugDoseRouteSchedule
Denosumab120 mgSubcutaneousEvery 4 weeks
Cycle length
Every 4 weeks
Duration
Continuous

Giant cell tumour and hypercalcaemia: 120 mg every 4 weeks with additional doses on days 8 and 15 of the first month. Calcium and vitamin D supplements; correct baseline calcium before starting [1].

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Side effects

For patients

The most common side effects: tiredness, weakness, low blood phosphate and calcium, nausea, diarrhoea and shortness of breath [1].

For physiciansSpecialist notes
For physicians

Common adverse reactions in solid tumours: fatigue/asthenia, hypophosphataemia, nausea; in myeloma: diarrhoea, nausea, anaemia, back pain, thrombocytopenia [1].

Serious side effects

For patients

Serious side effects: very low calcium (especially with kidney failure), damage to the jaw bone (osteonecrosis), unusual thigh bone fractures and spinal fractures after stopping the drug [1, 3].

For physiciansSpecialist notes
For physicians
  • Hypocalcaemia: monitor calcium before each dose in high-risk patients (clearance below 30 or dialysis) [1].
  • Osteonecrosis of the jaw: dental examination before starting, avoid unnecessary dental surgery [1, 3].
  • Atypical femoral fracture; multiple vertebral fractures after discontinuation [1].

When should I call my doctor?

  • Tingling around the mouth or in the fingers, muscle cramps (low calcium)
  • Pain, swelling or a sore in the jaw or gums, a loose tooth
  • New pain in the thigh or groin

Interactions, pregnancy and precautions

  • Teeth: have a dental check before starting; tell your doctor if you need a tooth taken out [3].
  • Stopping the drug: do not stop without a plan from your doctor; after stopping, the risk of spinal fractures goes up [1].
  • Pregnancy: this drug may harm an unborn baby; use effective contraception during treatment and tell your doctor straight away if you become pregnant. Do not breastfeed during treatment [1].
For patients

Frequently asked questions

What is the difference between Xgeva and Prolia?

Both are denosumab, but Xgeva (120 mg every month) is for cancer and Prolia (60 mg every 6 months) is for osteoporosis [1].

References

3 references
Show all referencesClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    XGEVA (DENOSUMAB) — Prescribing InformationAmgen, Inc · FDA label · 2026
    Source Back to text: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
  2. 2
    Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyStopeck AT, Lipton A, Body JJ, et al · J Clin Oncol · 2010;28:5132-9
    DOIPubMed Back to text: 1 2
  3. 3
    Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice GuidelineYarom N, Shapiro CL, Peterson DE, et al · J Clin Oncol · 2019;37:2270-2290
    DOIPubMed Back to text: 1 2 3 4

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.